The present invention concerns a pet litter comprising a composition comprising 2,2-dimethyl-1,3-dioxolane-4-methanol. The present invention further relates to methods and uses of a composition comprising 2,2-dimethyl-1,3-dioxolane-4-methanol in pet litters, in particular for promoting in-litter elimination by pets.

A novel sulfonium compound of formula (A) and a chemically amplified resist composition comprising the same as a PAG are provided. When processed by photolithography using KrF or ArF excimer laser, EB or EUV, the resist composition has a high sensitivity and reduced acid diffusion and is improved in lithography properties.

##STR00001##

A novel sulfonium compound of formula (A) and a chemically amplified resist composition comprising the same as a PAG are provided. When processed by photolithography using KrF or ArF excimer laser, EB or EUV, the resist composition has a high sensitivity and reduced acid diffusion and is improved in lithography properties.

##STR00001##

The present invention relates to a derivative of 13-oxidized ingenol, use thereof in the prevention and/or treatment of a disease associated with proliferation or tumor in a subject, or a cosmetic indication, and use thereof in the prevention and/or treatment of a disease responsive to neutrophil oxidative burst, a disease responsive to a release of IL-8 by keratinocyte, or a disease responsive to induction of necrosis.

The present disclosure relates to methods of carbon-carbon bond fragmentation.

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. ##STR00001## The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

There is provided a compound which is (a) a pyrimidine sulfonamide of formula (I) or (b) a pharmaceutically acceptable salt thereof, crystalline forms of the compound, processes for obtaining the compound, pharmaceutical intermediates used in the manufacture of the compound, and pharmaceutical compositions containing the compound. ##STR00001## The compound is useful in the treatment of a disease/condition in which modulation of chemokine receptor activity is beneficial.

A dioxolane derivative represented by formula (G1) is provided. The explanation of the substituents is given in the specification. The use of the dioxolane derivative enables the production of a liquid crystal composition and a liquid crystal display device including the liquid crystal composition. ##STR00001##

A dioxolane derivative represented by formula (G1) is provided. The explanation of the substituents is given in the specification. The use of the dioxolane derivative enables the production of a liquid crystal composition and a liquid crystal display device including the liquid crystal composition. ##STR00001##